Xcout IntelSign inSubscribe

Beta Bionics, Inc. competitors & alternatives

BBNXMedical DevicesIrvine, United States

The 12 closest competitors and alternatives to Beta Bionics, Inc. among medical devices companies — ranked by similarity to what Beta Bionics, Inc. actually does, not by market-cap band.

$873.7MMarket cap
423Employees
12Competitors listed

Subscribe to see Beta Bionics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About Beta Bionics, Inc.

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

Beta Bionics, Inc. at a glance

Beta Bionics, Inc. is a medical devices company headquartered in Irvine, United States. It is publicly listed (BBNX) with a market capitalisation of $873.7M. Xcout tracks 25 named people at Beta Bionics, Inc., including Sean T. Saint (President, Chief Executive Officer & Director).

Beta Bionics, Inc. leadership

  • Sean T. SaintPresident, Chief Executive Officer & Director
  • Sean SaintPresident, CEO Board Member
  • Stephen H. FeiderChief Financial Officer, Treasurer & Secretary
  • Stephen FeiderChief Financial Officer
  • Mike MensingerChief Product Officer
  • Mark HopmanChief Commercial Officer

19 more named people on record for Beta Bionics, Inc., with roles, board committees and tenure — see the full roster →

Beta Bionics, Inc. funding rounds on record

Every round on record:

DateRoundAmountInvestors
Series E$63M—
Series D$100M4 named
Series C$57M—

Some filings are not shown as funding rounds.

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Top 12 Beta Bionics, Inc. competitors

Ranked by semantic similarity — how close each company is to Beta Bionics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

Tandem Diabetes Care, Inc.TNDM · Medical DevicesSan Diego, United States
72% matchPublicAI 10/100Green 3/100 ▼

Similar medical devices company

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

Market cap$1.1B
Employees2,500
C#JavaScriptAWSAzureDocker
Tandem Diabetes Care, Inc. competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of Beta Bionics, Inc. and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for Beta Bionics, Inc.and every competitor above — in one live dashboard.

Subscribe to Xcout Intel →